Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of CD3-bispecifics and mitigate T cell exhaustion (AACR 2025) - Mar 26, 2025 - Abstract #3797; Pres time: Apr 28, 2025; 04:05 PM - 04:20 PM; Location: Room S102 - McCormick Place South (Level 1); P1 | "Finally, and perhaps most importantly, BiCo-1 also reverted T cell exhaustion induced by CC-1 single agent treatment in patient-derived T cells ex vivo.Taken together, these data demonstrate that the combinatorial use of bsAbCD3 and Bicos may profoundly enhance the sustainability and specificity of therapeutically induced T cell responses against tumors. The GMP-compliant production of BiCo-1 as well as preclinical evaluation in non-human primates has been completed, and a first-in-human clinical trial in prostate cancer patients is will begin recruitment in 2025."
Bispecific • Clinical • First-in-human • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • ABCD3 • ENG
|
|
Latifa Zekri; Nisha Prakash; Monika Engel; Timo Manz; Stefanie Müller; Jonas Heitmann; Sebastian Hörner; Ilona Hagelstein; Martin Pflügler; Gundram Jung; Helmut R. Salih
|